Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy

被引:1
|
作者
Tibensky, Miroslav [1 ,2 ]
Blasko, Filip [1 ,2 ]
Vargovic, Peter [2 ]
Jakubikova, Jana [3 ]
Cholujova, Dana [3 ]
Jakubechova, Jana [3 ]
Mravec, Boris [1 ,2 ]
机构
[1] Comenius Univ, Fac Med, Inst Physiol, Bratislava, Slovakia
[2] Slovak Acad Sci, Biomed Res Ctr, Inst Expt Endocrinol, Bratislava, Slovakia
[3] Slovak Acad Sci, Biomed Res Ctr, Canc Res Inst, Bratislava, Slovakia
关键词
B16F0; cells; immune system; lidocaine; melanoma; neurobiology of cancer; tetracaine; CELL SUBSETS; SYSTEM;
D O I
10.4149/neo_2023_230418N216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Experimental and clinical data have shown that the nervous system can significantly stimulate the initiation and progression of melanoma. In support of this, approaches that reduce the transmission of signals from peripheral nerves to effector tissues reduce the recurrence of melanoma. Therefore, we investigated the effect of topical application of the local anesthetic Pliaglis (7% lidocaine and 7% tetracaine) on the growth of melanoma induced by intradermal application of B16F0 cells in mice without treatment and in mice treated with the anti-PD-1 antibody. We found that application of Pliaglis to melanoma significantly reduced its growth and this effect was even pronounced in mice treated with the anti-PD-1 antibody. To determine the mechanisms and pathways responsible for the observed effect, the in vitro effect of incubating melanoma cells with lidocaine and/or tetracaine and the in vivo gene expression of cancer and immune-related factors, percentage of immune cells, gene expression of selected neurotransmitter receptors and nerve growth factors in melanoma tissue were studied. We found that lidocaine and tetracaine significantly reduced the viability of B16F0 cells in vitro. In mice with melanoma, Pliaglis potentiated the effect of anti-PD-1 antibody on gene expression of COX-2, IL-1 beta, IL-6, CCL11, F4/80, CD206, and NCR1. In addition, Pliaglis increased the gene expression of a9nACHR and 5-HT2a receptors and decreased the gene expression of nerve growth factor receptor (p75NTR) and p53. We also observed Pliaglis-mediated changes in myeloid populations. Topical application of this local anesthetic cream decreased the CD11b(+)Gr1(-) population and increased the CD11b(+)Gr1(high) population. Our data suggest that Pliaglis reduces melanoma growth through a direct effect on melanoma cells as well as through modulation of the immune response. The involvement of nervous system-related signaling in the inhibitory effect of Pliaglis on melanoma is inconclusive from our data.
引用
收藏
页码:375 / +
页数:16
相关论文
共 50 条
  • [41] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [42] Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.
    Roger, Anissa
    Finet, Adeline
    Boru, Blandine
    Mazeron, Jean-Jacques
    Otmezguine, Yves
    Blom, Astrid
    Longvert, Christine
    De Maleissye, Marie-Florence
    Beauchet, Alain
    Saiag, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [44] Management of Localized Melanoma in the Anti-PD-1 Era
    Novis, Elan
    van Akkooi, Alexander C. J.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (08) : 924 - 933
  • [45] Anti-PD-1 antibody treatment for melanoma Reply
    Beaver, Julia A.
    Keegan, Patricia
    Lemery, Steven
    Pazdur, Richard
    Theoret, Marc R.
    LANCET ONCOLOGY, 2018, 19 (05): : E220 - E220
  • [46] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [48] Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence
    Cybulska-Stopa, Bozena
    Rogala, Pawel
    Czarnecka, Anna M.
    Lugowska, Iwona
    Teterycz, Pawel
    Galus, Lukasz
    Rajczykowski, Marcin
    Dawidowska, Anna
    Piejko, Karolina
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    ADVANCES IN MEDICAL SCIENCES, 2020, 65 (02): : 316 - 323
  • [49] Intrinsic suppression of PD-L1 by SOX10 affects anti-PD-1 efficacy in melanoma
    Takahashi, Atsushi
    Yokoyama, Satoru
    Zhou, Yue
    Hayakawa, Yoshihiro
    Sakurai, Hiroaki
    CANCER SCIENCE, 2022, 113 : 513 - 513
  • [50] Immune alterations of response to anti-PD-1 therapy in melanoma-preliminary results
    Nemeth, V.
    Hunyadi, K.
    Gyulai, R.
    Lengyel, Z.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S198 - S198